AccurEdit Therapeutics’ LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA

CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ — AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001, which utilizes lipid nanoparticle (LNP)…